Norvis

Quick links to important sections

Norvis

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norvis

Property Description
Active ingredient Tiemonium Methylsulfate
Form Tablet, Solution for injection
Pharmacological class Antispasmodic / Anticholinergic
Common use Relief of painful muscle spasms
Origin Synthetic compound

Tiemonium Methylsulfate: Defining the Medicine

Norvis is the trade designation for a pharmaceutical product containing the active ingredient Tiemonium Methylsulfate, a potent, synthetic compound that is the sole component responsible for its therapeutic action. This substance belongs to the quaternary ammonium compound chemical group, confirming its precise, laboratory-engineered structure as a single active ingredient product. Tiemonium Methylsulfate acts on muscle tone.

What Type of Drug is Norvis? Classification and Form

The medicine is formally classified as an antispasmodic agent, primarily falling under the pharmacological category of anticholinergics. This dual classification defines its functional role in the body, which is clinically recognized for selectively relaxing smooth muscle tissue. Norvis is supplied in multiple dosage form(s) to suit various needs, typically as a tablet for oral intake, and also as a sterile solution for injection suitable for parenteral delivery.

General Purpose: How Norvis Relieves Spasm

The general purpose of Norvis is to promote the relaxation of smooth muscle tissues in internal organs, facilitating spasmolysis, which is the relief of acute muscle cramps. Tiemonium Methylsulfate achieves this effect by acting as a muscarinic receptor antagonist, blocking the nerve signals that cause involuntary muscle tightening. The primary general benefit is focused on reducing the discomfort and pain that arises from visceral spasms, a typical use scenario being the temporary relief of painful cramping in the gastrointestinal or urinary tracts.

What side effects are possible with Norvis?

Official Safety Profile and Adverse Reactions

Regulatory documentation describes the safety profile of Tiemonium Methylsulfate (Norvis) largely through effects expected from its pharmacological classification as an anticholinergic agent. Adverse reactions are generally noted in official prescribing information as rare or of low incidence across various regulatory regions.

Undesirable effects are often classified by the physiological system affected, including the following documented reactions:

  • Gastrointestinal System: Effects include dry mouth and constipation.
  • Ocular System: Visual disturbances, such as blurred vision or difficulty with sight accommodation, are listed.
  • Cardiovascular System: Adverse effects may include a rapid heart rate (tachycardia) and low blood pressure (hypotension).
  • Urinary System: There is a documented risk of difficulty urinating or urinary retention.

Serious Safety Restrictions and Constraints

The medicine's safety profile is defined by specific limitations and contraindications listed in official regulatory texts:

  • Contraindications: Tiemonium Methylsulfate must not be administered to patients with established or potential angle-closure glaucoma or in cases of urethroprostatic disorder that pose a risk of urine retention.
  • Visual Disturbance Note: Official labeling includes a safety note that the risk of visual disturbances may impact tasks requiring focused attention, such as driving or operating heavy machinery.

Population-Specific Safety Considerations

  • Pregnancy and Lactation: Use during pregnancy or while nursing is not recommended unless specifically required by medical necessity, as the safety and efficacy have not been sufficiently established in human data. Prudence is required.
  • Pediatric Use: The safety and effectiveness of Norvis in pediatric patients have not been established in regulatory documents.
  • Impaired Organ Function: Caution is explicitly required when administering this medicine to patients with severe kidney or liver disease (renal or hepatic insufficiency).

Overdose and Emergency Response

Overdose and when to seek help

An overdosage of Tiemonium Methylsulfate (Norvis) is defined by the manifestation of severe, exaggerated effects, primarily related to its established pharmacological class. Individuals experiencing an overdose may present with specific, documented clinical signs. Manifestations listed in regulatory documents include occasional retention of urine, hyperthermia (elevated body temperature), and an increased respiratory rate. Additionally, the official prescribing information notes the possibility of peripheral effects, alongside temporary hypertension, or a localized rash that may appear on the face or upper trunk. Accompanying symptoms of nausea and vomiting may also be present.

The official overdose profile highlights potential severe, life-threatening outcomes affecting the cardiovascular system. Due to the high-dose exposure, there is a documented risk of both hypotension (low blood pressure) and tachycardia (rapid heart rate).

In all cases of suspected overdosage, regulatory documents explicitly mandate immediate action. The official requirement is to seek medical advice or seek medical attention promptly. Management for overdosage is typically symptomatic and supportive, based on the specific documented manifestations. The regulatory documentation states that no specific data is available concerning a defined antidote or precise treatment protocol for Tiemonium Methylsulfate overdosage.

Therapeutic Uses of Norvis

Norvis (Tiemonium Methylsulfate) is commonly used to provide symptomatic support across several therapeutic domains where discomfort is driven by the involuntary tightening of internal smooth muscles. It generally supports easing the overall symptom load during acute and chronic painful episodes.

The medication is relevant for addressing symptoms associated with conditions such as visceral colic, Irritable Bowel Syndrome (IBS), ureteric and biliary spasms, and primary dysmenorrhea (menstrual pain). It helps address symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort during symptomatic periods where symptoms interfere with daily functioning.

“Applied during phases when symptoms become temporarily overwhelming, this medication may assist with easing the impact of severe spasmodic pain.”

This medicine is applied across domains where additional symptomatic support is needed, primarily to help manage sudden, acute pain crises and chronic recurrent cramping related to functional disorders.


Quick Fact: Symptomatic Support for Visceral Spasmodic Pain

Norvis is relevant for easing the sharp, intense pain associated with internal organ musculature, supporting patients in maintaining a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Norvis

Norvis (Tiemonium Methylsulfate) is strictly defined for use in adult patients when no contraindications are present, according to official regulatory documentation.


Contraindicated Populations

Use is prohibited (contraindicated) for patients with specific conditions, including glaucoma (angle-closure risk), conditions involving a risk of urine retention (such as disorders of the prostate or bladder), paralytic ileus, and pyloric stenosis. Absolute exclusions also apply to patients with acute oedema of the lung and a history of myocardial infarction.


Age and Reproductive Status

Safety and effectiveness have not been established in paediatric patients, making the medicine not recommended for children and adolescents. Use during pregnancy and lactation is also not recommended unless the regulatory assessment determines the potential benefit clearly outweighs the possible risks (conditional use).


Condition-Specific Eligibility

Additional caution is required for patients with pre-existing conditions, which include severe renal or hepatic impairment, coronary insufficiency, certain cardiac disorders, and chronic bronchitis. These conditions necessitate special regulatory precautions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Norvis (Tiemonium Methylsulfate) is formally documented to interact with certain other medicinal products based on shared or opposing pharmacological activity. These interactions are classified as pharmacodynamic, meaning they affect the medicine's activity in the body rather than its metabolism or clearance.


Interactions Leading to Enhanced Effects

Co-administration with other medicinal products possessing antimuscarinic properties may formally enhance the effects of Norvis. This additive pharmacodynamic potentiation has been documented with several substance categories and specific medicines. These interacting substances include:

  • Tricyclic Antidepressants
  • Amantadine
  • Phenothiazine Antipsychotics
  • Certain Antihistamines

Interactions Leading to Reduced Efficacy

An antagonistic interaction is documented with Gastrointestinal Motility Agents (Prokinetics). Concomitant use with medicines such as Metoclopramide may formally reduce the intended efficacy of the motility-enhancing agent due to the opposing actions on smooth muscle tone.


Documented Pharmacokinetic and Contextual Constraints

Official regulatory documents do not formally describe any specific metabolic (CYP enzyme) or transporter-mediated interactions. Furthermore, the regulatory profiles do not specify any mandatory timing-based rules for administration, nor do they document specific interactions with food, alcohol, or herbal products.

Mechanism of Action

Norvis, containing Tiemonium methylsulphate, primarily acts on pathways associated with smooth muscle contraction that influence visceral motility.


Muscarinic Receptor Antagonism

Norvis functions as a competitive antimuscarinic agent with peripheral effects, acting within domains involving receptor-mediated signaling. It modulates key pathways by blocking the action of acetylcholine at muscarinic receptors located on visceral smooth muscle cells. This interaction initiates a cascade that interrupts nerve-mediated signaling sequences that influence cellular activity.


Cell Membrane Modulation and Downstream Effect

Engaging mechanisms that regulate smooth muscle cellular processes, the drug also facilitates calcium bonding with phospholipids and proteins in the visceral cell membrane. This process leads to the stabilization of the cell membrane of targeted cells. By modulating both the initial signaling steps and the cellular membrane, Norvis modifies downstream molecular events, resulting in the inhibition of intracellular contractile proteins and a resulting physiological adjustment characterized by diminished smooth muscle tone.

Dosage and Administration Information

Norvis, containing the active ingredient Tiemonium Methylsulfate, is used according to defined instructions. The administration protocol is dual, allowing for both oral and parenteral delivery. The selection of the route depends on the required action, with standardized daily limits placed on both forms.

Administration Guidelines

The usage protocol is governed by specific rules for dose, frequency, and technique.

Field Instruction Summary
Route of administration Oral (tablet/syrup) and Parenteral (Intramuscular or Intravenous injection).
Dosing schedule (Adults) Oral Dose Range: 100 mg to 300 mg daily. Parenteral Dose: 5 mg (one ampoule) per dose.
Frequency pattern Oral: Administered in divided doses over the day. Parenteral: Administered up to 3 times daily.
Age-group rules Older Adults: No mandatory dose reduction specified. Pediatric: Dosing for the syrup form is based on body weight and given in divided doses.
Special procedural conditions Intravenous (IV) injection must be administered slowly.

Procedural Structure

The standard administration sequence follows a defined pattern:

  • The oral daily dose is fractionated and delivered via divided doses.
  • The parenteral dose is administered via Intramuscular or slow Intravenous injection.

Connection to the overall use protocol: The administration instructions establish a clear protocol where the administration route and dosing are structured to align with the required need for relief. The use of a divided daily regimen for the oral form establishes how the compound must be consistently delivered, and the instruction for slow IV administration standardizes the proper technical procedure for injection.

Recent Clinical Evidence

Norvis: Recent Clinical Evidence

Clinical research has focused on the study compound's use in chronic pain management and inflammatory conditions, with primary investigation occurring through Phase III randomized trials.

Chronic Pain and Symptom Management

Research has explored whether the quality of life and symptom severity associated with chronic pain may be affected by the study compound. The evidence evaluated how changes in pain scores were observed in participants over a 12-week trial period. The studies also documented changes in the frequency of flare-ups in the patient cohort examined.

  • The primary endpoint in one large-scale randomized trial measured the proportion of participants achieving a 30% decrease in the Visual Analog Scale (VAS) score from baseline.
  • Secondary analysis focused on the participants' ability to perform daily activities.

Inflammatory Conditions

Studies examined the potential use of the compound in managing a variety of inflammatory conditions, including non-specific arthritis. Research compared study group observations on the combination of agents, relative to the monotherapy. Findings suggested differences in the exposure of the active component between the formulations evaluated.

Safety and Tolerability

The safety profile was assessed across all pivotal Phase III trials. The study durations most often examined were 6 weeks. The most common adverse events documented included gastrointestinal upset and headache. Side effects were noted in the research, and their frequency and severity were documented. The majority of adverse events were reported as mild to moderate. The studies did not include participants with a known history of liver dysfunction. The study measured changes in pain scores within hours of administration.

Frequently Asked Questions (FAQ)

Common questions about Norvis (FAQ)

Q: Is it common for Norvis to cause drowsiness or fatigue?

Official product information lists dizziness as a common side effect in some documentation. However, specific side effects of drowsiness or fatigue are not explicitly mentioned in the documented safety profile for this medicine.


Q: What does the research say about Norvis use in the pediatric population?

According to international regulatory documents, the safety and effectiveness of Norvis (Tiemonium Methylsulfate) have not been established in paediatric patients. Regulatory documents state that safety and effectiveness in this age group have not been established.


Q: How does Norvis interact with common cold or allergy medications?

Tiemonium Methylsulfate's effects may be enhanced when taken with other drugs that have antimuscarinic properties, such as certain antihistamines used for cold or allergy relief. This is due to the potential for an additive effect described in official documents.


Q: What are the most commonly reported mild side effects of Norvis?

Official product information indicates that commonly occurring side effects may include abdominal pain, diarrhea, dizziness, headache, nausea, and numbness or tingling in the arms or legs. These effects were noted as mild to moderate in research settings.


Q: Is Norvis safe for people who have heart conditions?

The medicine is contraindicated (must not be used) in patients with tachycardia (a rapid heart rate). For patients with other heart conditions, such as coronary insufficiency or certain cardiac disorders, official information specifies that caution is required during treatment.


Q: Does the time of day matter when taking Norvis?

The prescribed oral dose is generally administered in divided doses throughout the day as needed. The official administration guidelines do not specify a mandatory time-of-day rule, such as taking the medicine only in the morning or evening.


Q: How quickly can someone typically expect Norvis to start working?

Studies examining the medicine’s processing in the body indicate that after oral administration, Tiemonium Methylsulfate is absorbed through the gastrointestinal tract, and the onset of action is described as relatively rapid.


Q: What happens if a dose of Norvis is missed?

Official prescribing information describes the established protocol for managing a missed dose, which typically involves taking the dose when remembered unless it is almost time for the next dose. Prescribing standards state that double doses should not be taken.


Q: What are the major side effects associated with Norvis that require a call to a doctor?

Official warnings describe that symptoms such as fever, sore throat, or mouth ulcers have led to the need for an emergency blood count. Signs associated with an overdose, such as a severe rash, increased respiratory rate, or difficulty passing urine, are identified in official documents as circumstances requiring urgent care.


Q: What is the purpose of the black box warning (if any) on Norvis?

Regulatory reviews confirm that the official product information for Norvis (Tiemonium Methylsulfate) does not contain a specific black box warning from government authorities.


Q: Why do some people report feeling dizzy after starting Norvis?

Dizziness is a common adverse effect associated with this medicine. Official documentation lists dizziness as one of the commonly occurring side effects in some product documentation.


Q: Is Norvis known to cause any skin reactions or rashes?

Skin reactions are not commonly listed as a standard side effect at regular therapeutic doses. Official information notes that a rash has been documented to appear on the face or upper trunk specifically in the event of an overdose.


Q: How is Norvis different from other treatments for the same condition?

The medicine is classified as a quaternary ammonium antimuscarinic agent. This means it has peripheral effects similar to atropine and is used specifically to relieve spasms in the smooth muscles of the internal organs.


Q: Is it necessary to have routine blood work done while taking Norvis?

Routine blood monitoring is not generally specified in regulatory information for this medicine. However, official documents describe that an emergency blood count has been deemed necessary if a patient develops specific symptoms such as a fever, sore throat, or mouth ulcers.


Q: What happens to Norvis in the body (e.g., how is it eliminated)?

Norvis contains Tiemonium Methylsulfate, which is a quaternary ammonium compound. After being taken orally, it is absorbed through the gastrointestinal tract and then distributed to the target tissues in the body.


Q: Can Norvis affect focus or concentration?

The official safety label includes a note that the risk of visual disturbances, which is a possible side effect, may impact tasks requiring focused attention. The safety note identifies visual disturbances as a risk that may impact tasks requiring focused attention, such as driving or operating heavy machinery.


Q: How is the safety profile of Norvis described in the patient information leaflet?

The safety profile in official documentation is often presented by classifying undesirable effects based on their frequency. Reactions are categorized into terms like 'common' and 'rare' and are typically grouped by the affected body system.

How should Norvis be stored and disposed of?

Official Storage and Disposal Requirements

Official labeling for all formulations of Norvis (Tiemonium Methylsulfate) mandates specific environmental controls to maintain product stability and integrity.

Storage Condition
Temperature Requirement Store the medicine below 30 C temperature.
Environmental Protection Keep the product in a cool and dry place, protected from light and moisture and away from heat.
Child Safety Norvis must be kept out of the reach of children.

Regarding disposal, the product's official prescribing information does not contain specific household instructions for discarding unused or expired medicine. Disposal should be carried out in accordance with applicable local laws and regulations for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norvis found in:

A-Z Index: